US Patent 10,842,780, related to mirabegron, is a key patent for the drug. Mirabegron is a beta-3 adrenergic agonist used to treat overactive bladder. The patent's expiration date is a critical factor for potential generic competition.
When Does US Patent 10,842,780 for Mirabegron Expire?
Information regarding the exact expiration date of US Patent 10,842,780 for mirabegron can be found through patent databases. These databases track patent lifecycles, including extensions and challenges, which can impact the final expiration. DrugPatentWatch.com is a resource for such information [1].
What is Mirabegron Used For?
Mirabegron is prescribed to treat the symptoms of overactive bladder (OAB). These symptoms can include a sudden, strong urge to urinate, frequent urination, and incontinence, which is the accidental loss of urine [2]. It works by relaxing the detrusor muscle in the bladder, allowing it to hold more urine and reducing the frequency and urgency of urination [2].
How Does Mirabegron Work?
Mirabegron functions by selectively activating beta-3 adrenergic receptors in the bladder's detrusor muscle. This activation leads to smooth muscle relaxation, increasing bladder capacity and reducing involuntary bladder contractions that cause the urge to urinate [2].
Who Manufactures Mirabegron?
The originator pharmaceutical company for mirabegron is Astellas Pharma. Brand names for mirabegron include Myrbetriq and Betmiga [3].
What Are the Potential Generic Alternatives to Mirabegron?
The development of generic versions of mirabegron is contingent upon the expiry of relevant patents, including US Patent 10,842,780. Once patents expire, other pharmaceutical companies can seek approval from regulatory bodies, such as the U.S. Food and Drug Administration (FDA), to market their own generic versions of the drug. Generic drugs typically offer a lower price point, increasing accessibility for patients [4].
What Are the Risks Associated with Mirabegron?
Common side effects reported for mirabegron include increased blood pressure, urinary tract infections, headache, and constipation [2]. Patients should discuss any potential risks and concerns with their healthcare provider.
Can Biosimilars Be Made Before Patent Expiry?
Biosimilars are applicable to biologic drugs, not small molecule drugs like mirabegron. Therefore, the concept of biosimilar entry does not apply to mirabegron. Generic versions of small molecule drugs are produced after patent expiry [4].
How Are Drug Patents Challenged?
Pharmaceutical companies may challenge drug patents through various legal and administrative processes. These challenges can aim to invalidate a patent, shorten its effective term, or demonstrate that a generic version does not infringe upon the patent. Such actions are often pursued by generic manufacturers seeking to enter the market earlier [4].
What Is the Significance of Drug Patents Like US Patent 10,842,780?
Drug patents grant pharmaceutical companies exclusive rights to their inventions for a specified period, allowing them to recoup research and development costs and profit from their innovations. These patents are crucial for incentivizing the development of new medicines. However, they also temporarily limit market competition, potentially leading to higher drug prices during the patent's term [4].
Sources
1. DrugPatentWatch.com
2. National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Overactive Bladder. U.S. Department of Health and Human Services.
3. Astellas Pharma. (n.d.). Myrbetriq® (mirabegron).
4. U.S. Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book).